GlassScriptPhysician profile
Oscar Galvis
NPI 1275517567
$1,039.97
in general payments reported to CMS, 2019-2025
18 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $262 · 2023: $208 · 2024: $229 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $548.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $187.66 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $111.32 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $97.80 | 2019-2025 | Austedo Xr, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $74.93 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $69.99 | 2019-2020 | |
| Lundbeck LLC | $68.38 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.44 | 2023 | Relistor |
| Tris Pharma INC | $57.57 | 2024-2025 | Dyanavel Xr |
| Neos Therapeutics, LP | $56.01 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $52.94 | 2024 | Relexxii |
| Otsuka America Pharmaceutical, INC. | $51.37 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $36.74 | 2019-2020 | |
| Shire North American Group INC | $27.91 | 2019 | |
| Sunovion Pharmaceuticals INC. | $21.57 | 2020 | |
| Idorsia Pharmaceuticals US INC | $19.29 | 2023 | Quviviq |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $14.84 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.77 | 2024 | Caplyta |
| Bausch Health US, LLC | $14.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oscar Galvis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.